Major breakthrough in Tigenix' Crohn's research

March 10, 2016 News BioVox

About one year ago, patients received a single injection of Cx601. Half of the patients were healed after 24 weeks. One year later, 1 in 2 (54%) patients still experiences the positive effect of the drug. This is very good news for TiGenix, because if diseases can be cured with a single injection, the probability increases that the product will be reimbursed by the health insurance. Previous studies already showed that the treatment has a favorable safety profile. Moreover, these results equip TiGenix with extra leverage to go to investors and pharma companies. The biotech company is looking for a pharmaceutical company to fund the last stage of the clinical trial in the US and wants to make an IPO on NASDAQ.


Avatar photo
BioVox

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter